KYNB
Kyntra Bio, Inc.
There isn't enough reported data to score KYNB yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
KYNB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
KYNB's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KYNB PE Valuation
KYNB has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
KYNB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect KYNB's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
KYNB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $45.20 | +$45.58 |
| Q1 2026 | $40.36 | +$42.86 |
| Q4 2025 | $45.37 | +$57.37 |
| Q3 2025 | $53.48 | +$83.98 |
| Q2 2025 | -$0.38 | +$42.12 |
| Q1 2025 | -$2.50 | +$58.50 |
| Q4 2024 | -$12.00 | +$61.00 |
| Q3 2024 | -$30.50 | +$46.00 |
KYNB has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
KYNB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $3.7M | +36% |
| Q2 2025 | $1.3M | -97% |
| Q1 2025 | $2.7M | -95% |
| Q3 2024 | $46.3M | +15% |
| Q2 2024 | $50.6M | +14% |
| Q1 2024 | $55.9M | +55% |
| Q4 2023 | $27.1M | -21% |
| Q3 2023 | $40.1M | +155% |
OSCR has the stronger quarterly revenue trend. Revenue is down 154% for KYNB versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -370% | +175 points |
| Q4 2025 | -1058% | N/A |
| Q2 2025 | -894% | -873 points |
| Q1 2025 | -545% | -489 points |
| Q3 2024 | -36% | +122 points |
| Q2 2024 | -22% | +177 points |
| Q1 2024 | -56% | +155 points |
| Q4 2023 | -200% | -7.2 points |
KYNB's operating margin was −370% last quarter, down 333 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
KYNB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4M | -132% |
| Q1 2026 | -$13.9M | -614% |
| Q4 2025 | -$18.3M | +$12.3M |
| Q3 2025 | -$1.9M | +$6.6M |
| Q2 2025 | $12.7M | +$52.6M |
| Q1 2025 | $2.7M | +$62M |
| Q4 2024 | -$30.6M | -$12M |
| Q3 2024 | -$8.5M | +$76.8M |
KYNB has burned cash in almost every quarter: −$38M over the past year, against −$24M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over KYNB on cash generation, producing positive trailing cash flow while its opponent burns cash.
KYNB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1K shares |
| 1 year | +0.1% | +6K shares |
| 3 years | +3.6% | +139K shares |
| 5 years | +9.7% | +357K shares |
| Available history | +16% | +568K shares |
KYNB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5,000 |
| Q4 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KYNB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2019 | -4.7x | Net Cash |
KYNB has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
KYNB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.1 | Oversold |
| Stochastic | 3.4 | Oversold |
KYNB's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KYNB PE vs Healthcare Sector
| Metric | KYNB | Sector median | Relative |
|---|---|---|---|
| PE | 0.1x | 26x | 100% below |
| PE % | 0 | 29 | 29 pts below |
KYNB has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KYNB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.09 | 29% below |
| 20 week MA | $6.52 | 45% below |
| 50 week MA | $7.17 | 50% below |
| 100 week MA | $8.50 | 58% below |
| 200 week MA | $70.4 | 95% below |
KYNB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over KYNB on trend strength, trading above more of its moving averages.
KYNB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,122.3 | $1,010.3 | -10% |
| 2021 | $1,010.3 | $384.8 | -62% |
| 2022 | $384.8 | $390.3 | +1.4% |
| 2023 | $390.3 | $22.2 | -94% |
| 2024 | $22.2 | $14.5 | -35% |
| 2025 | $14.5 | $8.90 | -39% |
| 2026 YTD | $8.90 | $3.59 | -60% |
KYNB has finished three years in a row lower, and it's down 60% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over KYNB on returns for 2026, with the stronger performance.